MX2020009459A - Moduladores de ror-gamma espirocíclico. - Google Patents

Moduladores de ror-gamma espirocíclico.

Info

Publication number
MX2020009459A
MX2020009459A MX2020009459A MX2020009459A MX2020009459A MX 2020009459 A MX2020009459 A MX 2020009459A MX 2020009459 A MX2020009459 A MX 2020009459A MX 2020009459 A MX2020009459 A MX 2020009459A MX 2020009459 A MX2020009459 A MX 2020009459A
Authority
MX
Mexico
Prior art keywords
ror
spirocyclic
gamma modulators
modulators
gamma
Prior art date
Application number
MX2020009459A
Other languages
English (en)
Inventor
Jason Harris
Raju Mohan
John Nuss
Shendong Yuan
Original Assignee
Escalier Biosciences B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Escalier Biosciences B V filed Critical Escalier Biosciences B V
Publication of MX2020009459A publication Critical patent/MX2020009459A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

En la presente se describen moduladores de receptores nucleares huérfanos (ROR) relacionados con ácido retinoico y métodos para utilizar moduladores de ROR-gamma en el tratamiento de enfermedades, trastornos o condiciones. En la presente también se describen composiciones farmacéuticas que contienen estos compuestos.
MX2020009459A 2018-03-12 2019-03-11 Moduladores de ror-gamma espirocíclico. MX2020009459A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862641949P 2018-03-12 2018-03-12
PCT/US2019/021671 WO2019177997A1 (en) 2018-03-12 2019-03-11 Spirocyclic ror-gamma modulators

Publications (1)

Publication Number Publication Date
MX2020009459A true MX2020009459A (es) 2021-01-15

Family

ID=67906868

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009459A MX2020009459A (es) 2018-03-12 2019-03-11 Moduladores de ror-gamma espirocíclico.

Country Status (11)

Country Link
US (2) US11242350B2 (es)
EP (1) EP3765020A4 (es)
JP (1) JP2021517565A (es)
KR (1) KR20210060367A (es)
CN (1) CN112118841A (es)
AU (1) AU2019234541A1 (es)
BR (1) BR112020018718A2 (es)
CA (1) CA3093695A1 (es)
EA (1) EA202092051A1 (es)
MX (1) MX2020009459A (es)
WO (1) WO2019177997A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021517563A (ja) 2018-03-12 2021-07-26 エスカリア バイオサイエンシーズ，ビーブイ 二環式ＲＯＲγモジュレーター
KR20210060367A (ko) 2018-03-12 2021-05-26 에스칼리에 바이오사이언시스, 비브이 스피로사이클릭 ror-감마 조절제

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432957B1 (en) 2001-06-29 2002-08-13 Kowa Co., Ltd. Piperazine derivative
AU2003280558A1 (en) 2002-10-11 2004-05-04 Kowa Co., Ltd. Method for treatment of cancer
TW201006816A (en) 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
TW201408652A (zh) * 2012-07-11 2014-03-01 Hoffmann La Roche 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
JP6407285B2 (ja) * 2013-09-09 2018-10-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＲＯＲγ調節因子
WO2016014910A1 (en) 2014-07-25 2016-01-28 Innov17 Llc Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof
EP3212641B1 (en) 2014-10-30 2018-12-05 Janssen Pharmaceutica NV Thiazoles as modulators of roryt
WO2016069978A1 (en) 2014-10-30 2016-05-06 Janssen Pharmaceutica Nv AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORγT
TWI667230B (zh) 2014-10-30 2019-08-01 比利時商健生藥品公司 用作ＲＯＲγｔ調節劑之三氟甲基醇
WO2017127442A1 (en) 2016-01-18 2017-07-27 The Regents Of The University Of California Methods for treating cancer with rorgamma inhibitors
TWI691486B (zh) 2016-01-29 2020-04-21 日商東麗股份有限公司 環狀胺衍生物及其醫藥用途
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
BR112019008548A2 (pt) 2016-10-27 2019-09-17 Escalier Biosciences Bv moduladores ror-gama
JP2021517563A (ja) 2018-03-12 2021-07-26 エスカリア バイオサイエンシーズ，ビーブイ 二環式ＲＯＲγモジュレーター
KR20210060367A (ko) 2018-03-12 2021-05-26 에스칼리에 바이오사이언시스, 비브이 스피로사이클릭 ror-감마 조절제

Also Published As

Publication number Publication date
JP2021517565A (ja) 2021-07-26
KR20210060367A (ko) 2021-05-26
EP3765020A1 (en) 2021-01-20
BR112020018718A2 (pt) 2021-03-09
EP3765020A4 (en) 2021-09-22
AU2019234541A1 (en) 2020-10-15
US20220106323A1 (en) 2022-04-07
US11242350B2 (en) 2022-02-08
EA202092051A1 (ru) 2021-03-04
US20210053976A1 (en) 2021-02-25
CN112118841A (zh) 2020-12-22
CA3093695A1 (en) 2019-09-19
WO2019177997A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
PH12019500949A1 (en) Ror-gamma modulators
JOP20230167A1 (ar) مساعدات مستقبل gpcr، وتركيبات صيدلانية تشتمل عليها، وطرق استخدامها
PH12017502052A1 (en) Substituted tetrahydroquinolinone compounds as ror gamma modulators
AU2017261336A1 (en) Modulators of the integrated stress pathway
EP4603142A3 (en) Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
AU2017260367A1 (en) Modulators of the integrated stress pathway
AU2017260374A1 (en) Modulators of the integrated stress pathway
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
MX2021015508A (es) Carbamatos de piridina y su uso como moduladores del receptor glun2b.
NZ737399A (en) Ccr2 modulators
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
MY208400A (en) Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof
MX2016010998A (es) Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
MX2020007731A (es) Compuestos moduladores de receptor de estrogeno.
MX2022000712A (es) Moduladores de nlrp3.
NZ757081A (en) Somatostatin modulators and uses thereof
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
EP4596543A3 (en) Farnesoid x receptor agonists and uses thereof
MX378098B (es) Derivados de piperazina como moduladores de ror?.
JOP20210328A1 (ar) مركبات أميدات بيريدين-بيرازولو المستبدلة واستخدامها باعتبارها معدِّلات لمستقبل الغلوتومات "glun2b"
MX2021015503A (es) Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b.
BR112021014566A2 (pt) Moduladores de gpr35